Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-09

Study Completion Date

2021-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Head trauma is a common injury in emergency department. Investigation to search for complication is guided by the clinical examination and the case history, such as taking anti-thrombotics. Cranial computed tomography (CCT) is the gold standard to investigate, and is mandatory in case of antithrombotic drugs.

Recently, some biomarkers have proven their utility to rule-out mild head trauma without CCT in the general population. Among these biomarkers, S100β protein has been added in guidelines for mild head trauma. Some studies have found similar data in population taking anticoagulant or antiplatelet drugs.

The investigators aim to prove medical utility of S100β protein in population under antithrombotics, by the reduction of CCT use. Then, The investigators hypothesize that the add of S100β protein reduces cost of health care in the management of head injury in that population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Performance of the S100B Protein in the Prognosis of Patients With Mild Head Trauma With Risk of Complications in Patients Over 65 Years Old.

NCT05091125

Mild Head Trauma With Risk of Complications

UNKNOWN

Interest of the S100B Protein Assay in Mild Traumatic Brain Injuries at the DOUAI Hospital

NCT05285774

Mild Brain Traumatic Injury Compliance, Patient

COMPLETED

Single-center Transversal Observational Study on the Evaluation of S100B Changes in Subjects Attending the Emergency Department With Head Trauma

NCT07036146

Head Trauma

RECRUITING

S-100B as Pre-Head CT Scan Screening Test After Mild Traumatic Brain Injury

NCT00717301

Traumatic Brain Injury

COMPLETED

S100 Protein in Minor/Mild Traumatic Brain Injury

NCT00822445

Minor/Mild Traumatic Brain Injury

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Head Injury Anticoagulant Antiplatelet

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dosage of S100β protein

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient ≥ 18 years old
* Taking antithrombotic medication (antiplatelet drugs, K vitamin antagonist, direct oral anticoagulants, heparins)
* Mild head trauma with Glasgow coma scale ≥ 13
* Trauma occured ≤ 6 hours
* Agreeing the participation in the study

Exclusion Criteria

* Head injury occured \> 6 hours
* Patient \< 18 years old or under juridic protection
* pregnant women
* polytrauma
* Glasgow coma scale ≤ 12
* ancient or actual cerebral ou cutaneous neoplasia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No